Enigma prevents Cbl-c-mediated ubiquitination and degradation of RETMEN2A

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Kales, Stephen C ^a   Nau, Marion M ^a   Merchant, Anand S ^b   Lipkowitz, Stanley ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL B PROTEIN; CBL C PROTEIN; CBL PROTEIN; LIM PROTEIN; PROTEIN PDLIM7; PROTEIN RET; PROTEIN RETMEN2A; PROTEIN TYROSINE KINASE; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ARTICLE; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RESIDUE ANALYSIS; UBIQUITINATION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; BREAST NEOPLASMS; CELLS, CULTURED; CYTOSKELETAL PROTEINS; FEMALE; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; LIM DOMAIN PROTEINS; MICROARRAY ANALYSIS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; PANCREATIC NEOPLASMS; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-CBL; PROTO-ONCOGENE PROTEINS C-RET; TWO-HYBRID SYSTEM TECHNIQUES; UBIQUITINATION;

EID: 84899878851     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087116     Document Type: Article

References (50)

1. Nau MM, Lipkowitz S (2003) Comparative genomic organization of the cbl genes. Gene 308: 103-113. (Pubitemid 36597828)
2. Nau MM, Lipkowitz S (2008) Welcome to the Family: Cbl-Famil Gene Organization, Overview of Structure and Functions of Cbl-Related Proteins in Various Taxonomical Groups. In: Tsygankov AY, editor. Cbl Proteins. 1 ed. New York: Nova Science Publishers, Inc. 3-25.
3. Schmidt MH, Dikic I (2005) The Cbl interactome and its functions. Nat Rev Mol Cell Biol 6: 907-918. (Pubitemid 41778710)
4. Davies GC, Ettenberg SA, Coats AO, Mussante M, Ravichandran S, et al. (2004) Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b. Oncogene 23: 7104-7115. (Pubitemid 39319172)
5. Peschard P, Kozlov G, Lin T, Mirza IA, Berghuis AM, et al. (2007) Structural basis for ubiquitin-mediated dimerization and activation of the ubiquitin protein ligase Cbl-b. Mol Cell 27: 474-485. (Pubitemid 47126940)
6. Griffiths EK, Sanchez O, Mill P, Krawczyk C, Hojilla CV, et al. (2003) Cbl-3-deficient mice exhibit normal epithelial development. Mol Cell Biol 23: 7708-7718. (Pubitemid 37271469)
7. Keane MM, Ettenberg SA, Nau MM, Banerjee P, Cuello M, et al. (1999) cbl-3: a new mammalian cbl family protein. Oncogene 18: 3365-3375. (Pubitemid 29286982)
8. Keane MM, Rivero-Lezcano OM, Mitchell JA, Robbins KC, Lipkowitz S (1995) Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. Oncogene 10: 2367-2377.
9. Langdon WY, Blake TJ (1990) The human CBL oncogene. Curr Top Microbiol Immunol 166: 159-164.
10. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, et al. (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4: 1029-1040. (Pubitemid 30054908)
11. Kim M, Tezuka T, Tanaka K, Yamamoto T (2004) Cbl-c suppresses v-Src-induced transformation through ubiquitin-dependent protein degradation. Oncogene 23: 1645-1655. (Pubitemid 38445157)
12. Bachmaier K, Krawczyk C, Kozieradzki I, Kong YY, Sasaki T, et al. (2000) Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b. Nature 403: 211-216. (Pubitemid 30050966)
13. Chiang YJ, Kole HK, Brown K, Naramura M, Fukuhara S, et al. (2000) Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216-220. (Pubitemid 30050967)
14. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, et al. (1998) Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol 18: 4872-4882. (Pubitemid 28343071)
15. Naramura M, Kole HK, Hu RJ, Gu H (1998) Altered thymic positive selection and intracellular signals in Cbl-deficient mice. Proc Natl Acad Sci U S A 95: 15547-15552. (Pubitemid 29018736)
16. Durick K, Gill GN, Taylor SS (1998) Shc and Enigma are both required for mitogenic signaling by Ret/ptc2. Mol Cell Biol 18: 2298-2308. (Pubitemid 28152677)
17. Guy PM, Kenny DA, Gill GN (1999) The PDZ domain of the LIM protein enigma binds to beta-tropomyosin. Mol Biol Cell 10: 1973-1984. (Pubitemid 29272644)
18. Bach I (2000) The LIM domain: regulation by association. Mech Dev 91: 5-17.
19. Wu RY, Gill GN (1994) LIM domain recognition of a tyrosine-containing tight turn. J Biol Chem 269: 25085-25090.
20. Durick K, Wu RY, Gill GN, Taylor SS (1996) Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain. J Biol Chem 271: 12691- 12694.
21. Takahashi M, Cooper GM (1987) ret transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 7: 1378-1385. (Pubitemid 17045226)
22. Parisi MA, Kapur RP (2000) Genetics of Hirschsprung disease. Curr Opin Pediatr 12: 610-617.
23. Hansford JR, Mulligan LM (2000) Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 37: 817-827.
24. Gujral TS, Mulligan LM (2006) Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2. Ann N Y Acad Sci 1073: 234-240. (Pubitemid 44912017)
25. Ettenberg SA, Keane MM, Nau MM, Frankel M, Wang LM, et al. (1999) cbl-b inhibits epidermal growth factor receptor signaling. Oncogene 18: 1855-1866. (Pubitemid 29145853)
26. Scott RP, Eketjall S, Aineskog H, Ibanez CF (2005) Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem 280: 13442-13449. (Pubitemid 40517232)
27. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, et al. (2011) A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305: 1873-1881.
28. Kao KJ, Chang KM, Hsu HC, Huang AT (2011) Correlation of microarraybased breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11: 143.
29. Wu R, Durick K, Songyang Z, Cantley LC, Taylor SS, et al. (1996) Specificity of LIM domain interactions with receptor tyrosine kinases. J Biol Chem 271: 15934-15941. (Pubitemid 26236204)
30. Pierchala BA, Milbrandt J, Johnson EM, Jr. (2006) Glial cell line-derived neurotrophic factor-dependent recruitment of Ret into lipid rafts enhances signaling by partitioning Ret from proteasome-dependent degradation. J Neurosci 26: 2777-2787. (Pubitemid 43357861)
31. Tsui CC, Pierchala BA (2008) CD2AP and Cbl-3/Cbl-c constitute a critical checkpoint in the regulation of ret signal transduction. J Neurosci 28: 8789- 8800.
32. Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M (1990) Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 5: 97-102. (Pubitemid 20044809)
33. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, et al. (2007) Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282: 29230-29240. (Pubitemid 350043334)
34. Santarpia L, Bottai G (2013) Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers. Curr Pharm Des 19: 864-882.
35. Davies GC, Ryan PE, Rahman L, Zajac-Kaye M, Lipkowitz S (2006) EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins. Oncogene 25: 6497-6509. (Pubitemid 44607082)
36. Ryan PE, Kales SC, Yadavalli R, Nau MM, Zhang H, et al. (2012) Cbl-c ubiquitin ligase activity is increased via the interaction of its RING finger domain with a LIM domain of the paxillin homolog, Hic 5. PLoS One 7: e49428.
37. Treier M, Staszewski LM, Bohmann D (1994) Ubiquitin-dependent c-Jun degradation in vivo is mediated by the delta domain. Cell 78: 787-798. (Pubitemid 24294454)
38. Borrello MG, Smith DP, Pasini B, Bongarzone I, Greco A, et al. (1995) RET activation by germline MEN2A and MEN2B mutations. Oncogene 11: 2419- 2427.
39. Richardson DS, Rodrigues DM, Hyndman BD, Crupi MJ, Nicolescu AC, et al. (2012) Alternative splicing results in RET isoforms with distinct trafficking properties. Mol Biol Cell 23: 3838-3850.
40. Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, et al. (1993) Characterization of the ret proto-oncogene products expressed in mouse L cells. Oncogene 8: 2925-2929. (Pubitemid 23312895)
41. Trupp M, Raynoschek C, Belluardo N, Ibanez CF (1998) Multiple GPI-anchored receptors control GDNF-dependent and independent activation of the c-Ret receptor tyrosine kinase. Mol Cell Neurosci 11: 47-63. (Pubitemid 28235179)
42. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, et al. (2006) Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 13: 1109-1120. (Pubitemid 46212566)
43. Boulay A, Breuleux M, Stephan C, Fux C, Brisken C, et al. (2008) The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res 68: 3743-3751.
44. Esseghir S, Todd SK, Hunt T, Poulsom R, Plaza-Menacho I, et al. (2007) A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res 67: 11732-11741.
45. Wang C, Mayer JA, Mazumdar A, Brown PH (2012) The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogendependent gene required for the growth of estrogen receptor positive breast cancer cells. Breast Cancer Res Treat 133: 487-500.
46. Jung CR, Lim JH, Choi Y, Kim DG, Kang KJ, et al. (2010) Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. J Clin Invest 120: 4493-4506.
47. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275: 8945-8951. (Pubitemid 30180252)
48. Lipkowitz S, Weissman AM (2011) RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 11: 629-643.
49. Ettenberg SA, Magnifico A, Cuello M, Nau MM, Rubinstein YR, et al. (2001) Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 276: 27677-27684.
50. Zeng S, Xu Z, Lipkowitz S, Longley JB (2005) Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl). Blood 105: 226-232. (Pubitemid 40053087)